Haemonetics (NYSE: HAE) revenue
Haemonetics reported revenue of $1,334m for fiscal 2026, 2.0% less than in fiscal 2025 ($1,361m). Since fiscal 2017 its revenue has grown by 50.5%, an average growth of 4.7% a year.
Haemonetics's best year of the last 10 was fiscal 2025. The biggest drop was in fiscal 2021, −11.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2026 | $1,334m | −2.0% | $156.7m | 11.7% |
| 2025 | $1,361m | +4.0% | $221.8m | 16.3% |
| 2024 | $1,309m | +12.0% | $164.9m | 12.6% |
| 2023 | $1,169m | +17.7% | $156.0m | 13.4% |
| 2022 | $993.2m | +14.1% | $80.8m | 8.1% |
| 2021 | $870.5m | −11.9% | $89.7m | 10.3% |
| 2020 | $988.5m | +2.2% | $103.4m | 10.5% |
| 2019 | $967.6m | +7.0% | $83.5m | 8.6% |
| 2018 | $903.9m | +2.0% | $56.2m | 6.2% |
| 2017 | $886.1m | — | −$19.4m | −2.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Haemonetics revenue compared with its sector
By revenue for its latest fiscal year, Haemonetics ranks 134th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Haemonetics, −2.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 132nd | LivaNova | $1,388m | 10.7% |
| 133rd | Conmed | $1,375m | 5.2% |
| 134th | Haemonetics | $1,334m | −2.0% |
| 135th | HealthEquity | $1,313m | 9.5% |
| 136th | Progyny | $1,289m | 10.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Haemonetics
- How much revenue did Haemonetics make in fiscal 2026?
- Haemonetics reported revenue of $1,334m for fiscal 2026, compared with $1,361m in fiscal 2025.
- How much has the revenue of Haemonetics grown?
- Between fiscal 2017 and fiscal 2026 it went from $886.1m to $1,334m: 50.5% more, an average growth of 4.7% a year.
- What was the best year for revenue at Haemonetics?
- Of its last 10 fiscal years, fiscal 2025, with $1,361m.
- Where does Haemonetics rank in its sector by revenue?
- It ranks 134th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Haemonetics come from?
- From the annual report (Form 10-K) that Haemonetics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Haemonetics files with the SEC. The filing for each fiscal year: 2026 · 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Haemonetics: the Haemonetics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.